{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:29Z","timestamp":1790346689476,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773255"],"award-info":[{"award-number":["81773255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972888"],"award-info":[{"award-number":["81972888"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700037"],"award-info":[{"award-number":["81700037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472820"],"award-info":[{"award-number":["81472820"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011444","name":"Jiangsu Key Laboratory for the Research and Utilization of Plant Resources","doi-asserted-by":"publisher","award":["BE2018701"],"award-info":[{"award-number":["BE2018701"]}],"id":[{"id":"10.13039\/501100011444","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s13402-021-00633-w","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T06:03:01Z","timestamp":1630994581000},"page":"1243-1255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma"],"prefix":"10.1007","volume":"44","author":[{"given":"Hailin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0883-1824","authenticated-orcid":false,"given":"Jiwu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"633_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"J.M. Llovet, R.K. Kelley, A. Villanueva, A.G. Singal, E. Pikarsky, S. Roayaie, R. Lencioni, K. Koike, J. Zucman-Rossi, R.S. Finn, Hepatocellular carcinoma. Nat Rev Dis Primers 7, 6 (2021)","journal-title":"Nat Rev Dis Primers"},{"key":"633_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhep.2019.11.006","volume":"72","author":"JC Nault","year":"2020","unstructured":"J.C. Nault, A.L. Cheng, B. Sangro, J.M. Llovet, Milestones in the pathogenesis and management of primary liver cancer. J Hepatol 72, 209\u2013214 (2020)","journal-title":"J Hepatol"},{"key":"633_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2019.12.002","volume":"470","author":"Z Yin","year":"2020","unstructured":"Z. Yin, X. Li, Immunotherapy for hepatocellular carcinoma. Cancer Lett 470, 8\u201317 (2020)","journal-title":"Cancer Lett"},{"key":"633_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/hep.26605","volume":"59","author":"S Vilarinho","year":"2014","unstructured":"S. Vilarinho, T.H. Taddei, New frontier in liver cancer treatment: oncolytic viral therapy. Hepatology 59, 343\u2013346 (2014)","journal-title":"Hepatology"},{"key":"633_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/nrgastro.2017.153","volume":"15","author":"J Altomonte","year":"2018","unstructured":"J. Altomonte, Liver cancer: Sensitizing hepatocellular carcinoma to oncolytic virus therapy. Nat Rev Gastroenterol Hepatol 15, 8\u201310 (2018)","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"633_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","volume":"13","author":"MJ Smyth","year":"2016","unstructured":"M.J. Smyth, S.F. Ngiow, A. Ribas, M.W. Teng, Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13, 143\u2013158 (2016)","journal-title":"Nat Rev Clin Oncol"},{"key":"633_CR7","doi-asserted-by":"crossref","unstructured":"J. Li, Y. Lee, Y. Li, Y. Jiang, H. Lu, W. Zang, X. Zhao, L. Liu, Y. Chen, H. Tan, Z. Yang, M.Q. Zhang, T.W. Mak, L. Ni and C. Dong, Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8(+) T cells, Immunity 48, 773\u2013786 e775 (2018)","DOI":"10.1016\/j.immuni.2018.03.018"},{"key":"633_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.immuni.2018.06.003","volume":"48","author":"BA Helmink","year":"2018","unstructured":"B.A. Helmink, P.O. Gaudreau, J.A. Wargo, Immune checkpoint blockade across the cancer care continuum. Immunity 48, 1077\u20131080 (2018)","journal-title":"Immunity"},{"key":"633_CR9","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.ymthe.2019.07.013","volume":"27","author":"MM Soldevilla","year":"2019","unstructured":"M.M. Soldevilla, H. Villanueva, D. Meraviglia-Crivelli, A.P. Menon, M. Ruiz, J. Cebollero, M. Villalba, B. Moreno, T. Lozano, D. Llopiz, A. Pejenaute, P. Sarobe, F. Pastor, ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity. Mol Ther 27, 1878\u20131891 (2019)","journal-title":"Mol Ther"},{"key":"633_CR10","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Y Kong","year":"2016","unstructured":"Y. Kong, L. Zhu, T.D. Schell, J. Zhang, D.F. Claxton, W.C. Ehmann, W.B. Rybka, M.R. George, H. Zeng, H. Zheng, T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res 22, 3057\u20133066 (2016)","journal-title":"Clin Cancer Res"},{"key":"633_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"X. Yu, K. Harden, L.C. Gonzalez, M. Francesco, E. Chiang, B. Irving, I. Tom, S. Ivelja, C.J. Refino, H. Clark, D. Eaton, J.L. Grogan, The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10, 48\u201357 (2009)","journal-title":"Nat Immunol"},{"key":"633_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","volume":"38","author":"NA Manieri","year":"2017","unstructured":"N.A. Manieri, E.Y. Chiang, J.L. Grogan, TIGIT: A key inhibitor of the cancer immunity cycle. Trends Immunol 38, 20\u201328 (2017)","journal-title":"Trends Immunol"},{"key":"633_CR13","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"JM Chauvin","year":"2015","unstructured":"J.M. Chauvin, O. Pagliano, J. Fourcade, Z. Sun, H. Wang, C. Sander, J.M. Kirkwood, T.H. Chen, M. Maurer, A.J. Korman, H.M. Zarour, TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest 125, 2046\u20132058 (2015)","journal-title":"J Clin Invest"},{"key":"633_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"R.J. Johnston, L. Comps-Agrar, J. Hackney, X. Yu, M. Huseni, Y. Yang, S. Park, V. Javinal, H. Chiu, B. Irving, D.L. Eaton, J.L. Grogan, The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26, 923\u2013937 (2014)","journal-title":"Cancer Cell"},{"key":"633_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"F.S. Hodi, S.J. O\u2019Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, W. Akerley, A.J. van den Eertwegh, J. Lutzky, P. Lorigan, J.M. Vaubel, G.P. Linette, D. Hogg, C.H. Ottensmeier, C. Lebbe, C. Peschel, I. Quirt, J.I. Clark, J.D. Wolchok, J.S. Weber, J. Tian, M.J. Yellin, G.M. Nichol, A. Hoos, W.J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711\u2013723 (2010)","journal-title":"N Engl J Med"},{"key":"633_CR16","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, P.D. Leming, D.R. Spigel, S.J. Antonia, L. Horn, C.G. Drake, D.M. Pardoll, L. Chen, W.H. Sharfman, R.A. Anders, J.M. Taube, T.L. McMiller, H. Xu, A.J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G.D. Kollia, A. Gupta, J.M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443\u20132454 (2012)","journal-title":"N Engl J Med"},{"key":"633_CR17","doi-asserted-by":"crossref","unstructured":"D. Zamarin, R.B. Holmgaard, S.K. Subudhi, J.S. Park, M. Mansour, P. Palese, T. Merghoub, J.D. Wolchok and J.P. Allison, Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy, Sci Transl Med 6, 226ra232 (2014)","DOI":"10.1126\/scitranslmed.3008095"},{"key":"633_CR18","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"L. Chen, X. Han, Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125, 3384\u20133391 (2015)","journal-title":"J Clin Invest"},{"key":"633_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"K. Harrington, D.J. Freeman, B. Kelly, J. Harper, J.C. Soria, Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov 18, 689\u2013706 (2019)","journal-title":"Nat Rev Drug Discov"},{"key":"633_CR20","doi-asserted-by":"crossref","unstructured":"M.A. Postow, Managing immune checkpoint-blocking antibody side effects, Am Soc Clin Oncol Educ Book, 76\u201383 (2015)","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"key":"633_CR21","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","volume":"27","author":"J Naidoo","year":"2016","unstructured":"J. Naidoo, D.B. Page, B.T. Li, L.C. Connell, K. Schindler, M.E. Lacouture, M.A. Postow, J.D. Wolchok, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 27, 1362 (2016)","journal-title":"Ann Oncol"},{"key":"633_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.mayocp.2019.03.012","volume":"94","author":"JA Marin-Acevedo","year":"2019","unstructured":"J.A. Marin-Acevedo, R.M. Chirila, R.S. Dronca, Immune checkpoint inhibitor toxicities. Mayo Clin Proc 94, 1321\u20131329 (2019)","journal-title":"Mayo Clin Proc"},{"key":"633_CR23","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/mt.2015.115","volume":"23","author":"N Woller","year":"2015","unstructured":"N. Woller, E. Gurlevik, B. Fleischmann-Mundt, A. Schumacher, S. Knocke, A.M. Kloos, M. Saborowski, R. Geffers, M.P. Manns, T.C. Wirth, S. Kubicka, F. Kuhnel, Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol Ther 23, 1630\u20131640 (2015)","journal-title":"Mol Ther"},{"key":"633_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","volume":"61","author":"RR Ji","year":"2012","unstructured":"R.R. Ji, S.D. Chasalow, L. Wang, O. Hamid, H. Schmidt, J. Cogswell, S. Alaparthy, D. Berman, M. Jure-Kunkel, N.O. Siemers, J.R. Jackson, V. Shahabi, An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61, 1019\u20131031 (2012)","journal-title":"Cancer Immunol Immunother"},{"key":"633_CR25","doi-asserted-by":"crossref","unstructured":"S. Spranger, R.M. Spaapen, Y. Zha, J. Williams, Y. Meng, T.T. Ha and T.F. Gajewski, Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells, Sci Transl Med 5, 200ra116 (2013)","DOI":"10.1126\/scitranslmed.3006504"},{"key":"633_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","volume":"39","author":"S Gujar","year":"2018","unstructured":"S. Gujar, J.G. Pol, Y. Kim, P.W. Lee, G. Kroemer, Antitumor benefits of antiviral immunity: An underappreciated aspect of oncolytic virotherapies. Trends Immunol 39, 209\u2013221 (2018)","journal-title":"Trends Immunol"},{"key":"633_CR27","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1245\/s10434-018-6803-0","volume":"25","author":"MC Perez","year":"2018","unstructured":"M.C. Perez, J.T. Miura, S.M.H. Naqvi, Y. Kim, A. Holstein, D. Lee, A.A. Sarnaik, J.S. Zager, Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: A single-institution experience. Ann Surg Oncol 25, 3960\u20133965 (2018)","journal-title":"Ann Surg Oncol"},{"key":"633_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1517\/14712598.2015.1044433","volume":"15","author":"TD de Gruijl","year":"2015","unstructured":"T.D. de Gruijl, A.B. Janssen, V.W. van Beusechem, Arming oncolytic viruses to leverage antitumor immunity. Expert Opin Biol Ther 15, 959\u2013971 (2015)","journal-title":"Expert Opin Biol Ther"},{"key":"633_CR29","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-16-1638","volume":"77","author":"MY Bartee","year":"2017","unstructured":"M.Y. Bartee, K.M. Dunlap, E. Bartee, Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy. Cancer Res 77, 2952\u20132963 (2017)","journal-title":"Cancer Res"},{"key":"633_CR30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/ijc.29068","volume":"136","author":"S Parviainen","year":"2015","unstructured":"S. Parviainen, M. Ahonen, I. Diaconu, A. Kipar, M. Siurala, M. Vaha-Koskela, A. Kanerva, V. Cerullo, A. Hemminki, GMCSF-armed vaccinia virus induces an antitumor immune response. Int J Cancer 136, 1065\u20131072 (2015)","journal-title":"Int J Cancer"},{"key":"633_CR31","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1158\/1078-0432.CCR-06-0935","volume":"12","author":"YS Lee","year":"2006","unstructured":"Y.S. Lee, J.H. Kim, K.J. Choi, I.K. Choi, H. Kim, S. Cho, B.C. Cho, C.O. Yun, Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7\u20131 in an immunocompetent murine model. Clin Cancer Res 12, 5859\u20135868 (2006)","journal-title":"Clin Cancer Res"},{"key":"633_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/mt.2013.240","volume":"22","author":"F Yu","year":"2014","unstructured":"F. Yu, X. Wang, Z.S. Guo, D.L. Bartlett, S.M. Gottschalk, X.T. Song, T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 22, 102\u2013111 (2014)","journal-title":"Mol Ther"},{"key":"633_CR33","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-17-2651","volume":"24","author":"T Speck","year":"2018","unstructured":"T. Speck, J.P.W. Heidbuechel, R. Veinalde, D. Jaeger, C. von Kalle, C.R. Ball, G. Ungerechts, C.E. Engeland, Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clin Cancer Res 24, 2128\u20132137 (2018)","journal-title":"Clin Cancer Res"},{"key":"633_CR34","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.surg.2015.01.006","volume":"157","author":"CJ LaRocca","year":"2015","unstructured":"C.J. LaRocca, J. Han, T. Gavrikova, L. Armstrong, A.R. Oliveira, R. Shanley, S.M. Vickers, M. Yamamoto, J. Davydova, Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery 157, 888\u2013898 (2015)","journal-title":"Surgery"},{"key":"633_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","volume":"18","author":"K Twumasi-Boateng","year":"2018","unstructured":"K. Twumasi-Boateng, J.L. Pettigrew, Y.Y.E. Kwok, J.C. Bell, B.H. Nelson, Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer 18, 419\u2013432 (2018)","journal-title":"Nat Rev Cancer"},{"key":"633_CR36","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ymthe.2019.07.019","volume":"27","author":"Y Zhang","year":"2019","unstructured":"Y. Zhang, H. Zhang, M. Wei, T. Mou, T. Shi, Y. Ma, X. Cai, Y. Li, J. Dong, J. Wei, Recombinant adenovirus expressing a soluble fusion protein PD-1\/CD137L subverts the suppression of CD8(+) T cells in HCC. Mol Ther 27, 1906\u20131918 (2019)","journal-title":"Mol Ther"},{"key":"633_CR37","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s11262-017-1488-1","volume":"53","author":"J Niemann","year":"2017","unstructured":"J. Niemann, F. Kuhnel, Oncolytic viruses: adenoviruses. Virus Genes 53, 700\u2013706 (2017)","journal-title":"Virus Genes"},{"key":"633_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.omto.2020.11.001","volume":"20","author":"H Zhang","year":"2021","unstructured":"H. Zhang, Y. Zhang, J. Dong, B. Li, C. Xu, M. Wei, J. Wu, J. Wei, Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance. Mol Ther Oncolytics 20, 12\u201322 (2021)","journal-title":"Mol Ther Oncolytics"},{"key":"633_CR39","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000124981","volume":"75","author":"U Hegde","year":"2008","unstructured":"U. Hegde, A. Chhabra, S. Chattopadhyay, R. Das, S. Ray, N.G. Chakraborty, Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes. Pathobiology 75, 200\u2013208 (2008)","journal-title":"Pathobiology"},{"key":"633_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.omto.2019.03.004","volume":"13","author":"G Meng","year":"2019","unstructured":"G. Meng, Z. Fei, M. Fang, B. Li, A. Chen, C. Xu, M. Xia, D. Yu, J. Wei, Fludarabine as an adjuvant improves Newcastle Disease Virus-mediated antitumor immunity in hepatocellular carcinoma. Mol Ther Oncolytics 13, 22\u201334 (2019)","journal-title":"Mol Ther Oncolytics"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-021-00633-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-021-00633-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-021-00633-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T10:39:54Z","timestamp":1638787194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-021-00633-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1007\/s13402-021-00633-w","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"assertion":[{"value":"25 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were conducted with approval of the Ethics Committee of Nanjing University Medical School. Animal welfare was closely monitored in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No consent was involved in this publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}